TAZORAC — Class II drug recall D-0100-2017
Terminated recall by Allergan Sales, LLC, reported 2016-10-19, distributed nationwide. Failed Content Uniformity Specifications
| Recall number | D-0100-2017 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Allergan Sales, LLC, Waco, TX, United States |
| Recall initiated | 2016-06-30 |
| Classified | 2016-10-13 |
| Reported by FDA | 2016-10-19 |
| Terminated | 2017-12-06 |
| Distributed | Nationwide (US) |
| Quantity | 17,112 tubes |
| UPC / GTIN / UDI-DI | 00300238335159 |
| Lot numbers | 05/17, 10/16, 82583, 85037 |
Product
TAZORAC (tazarotene) Gel 0.05%, Rx only, packaged in 15 x 3.5 g professional sample containers, Manufactured by: Allergan Inc., Irvine, CA 92512. UPC: 300238335159.
Reason for recall
Failed Content Uniformity Specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0100-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.